Aids-related plasmablastic lymphoma of the oral cavity associated with an IgH/MYC translocation treatment with autologous stem-cell transplantation in a patient with severe haemophilia-A

Dawson, Mark A.; Schwarer, Anthony P.; McLean, Catriona; Oei, Paul; Campbell, Lynda J.; Wright, Edwina; Shortt, Jake; Street, Alison

doi:10.3324/haematol.10933

Cited by 43 publications

(47 citation statements)

References 9 publications

(9 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In South Africa PBL is a neoplasm mostly related to HIV infection and we concur with others that the varies from a few weeks to 3 years but seems to be reduced substantially when MYC rearrangements are present [9][10][11] .…”

Section: Discussionsupporting

confidence: 66%

Dominant genetic aberrations and coexistent EBV infection in HIV-related oral plasmablastic lymphomas

et al. 2011

View full text Add to dashboard Cite

SUMMARYWe present common cytogenetic features in the largest cohort of plasmablastic lymphoma (PBL) of the oral cavity published to date. This cohort included 45 patients, 32 of whom had a known HIV status, of which thirty one were HIV positive. Ninety eight per cent of all PBL cases were known to be EBV positive. In line with previous studies, we found that rearrangements of the MYC gene was the most common genetic abnormality seen in 60% of cases with the immunoglobulin heavy chain (IGH) locus as a partner in 51% of cases. Additional complex genetic aberrations were frequent, in particular, an increased copy number of the CCND1 gene was seen in 41% of cases with true amplification of CCND1 in 15% of cases. Aneuploidy was also observed for the BCL6 gene in 28% of cases. Interestingly, rearrangements of both IGH genes were detected in 16% of cases with t(14;18) and t(11;14) respectively involved in conjunction with a t(8;14) in two cases. These bi-allelic IGH rearrangements have not been described before in oral PBL. Our results reinforce the notion that EBV infection and MYC rearrangements are important events in the pathogenesis of oral PBL. The genetic diversity and complexity observed in these cases, underlines the importance to genetically characterise PBL patients at presentation as this may inform the choice of more effective treatment modalities.3

show abstract

Section: Discussionsupporting

confidence: 66%

Dominant genetic aberrations and coexistent EBV infection in HIV-related oral plasmablastic lymphomas

et al. 2011

View full text Add to dashboard Cite

show abstract

“…In our report, only two patients were treated with autologous SCT. One case was a 36-year-old man with hemophilia A, who acquired HIV through a blood transfusion [8]. This patient died of PBL 14 months after the diagnosis.…”

Section: Discussionmentioning

confidence: 99%

HIV‐associated plasmablastic lymphoma: Lessons learned from 112 published cases

2008

View full text Add to dashboard Cite

Plasmablastic lymphoma (PBL) is a distinct subtype of non-Hodgkin B-cell lymphoma, originally described with a strong predilection to the oral cavity of human immunodeficiency virus (HIV)-infected individuals. Data regarding patient age and gender, HIV status, initiation of and response to highly active antiretroviral therapy (HAART), tumor extent, pathology, treatment, and outcome were extracted from 112 cases of PBL identified in the literature. The median age at presentation was 38 years with a male predominance of 7:1, and the median CD41 count was 178 cells/mm 3 . PBL presented on average 5 years after diagnosis of HIV. Common primary sites of presentation included the oral cavity, gastrointestinal tract, and lymph nodes. Most cases presented with either stage I or stage IV disease. There was a variable expression of B-cell markers in tumor cells, but plasma cell markers were expressed in all cases. EBV was detected in 74%. Chemotherapy was used to treat 55% patients and was combined with radiotherapy in 21% cases. Complete response was obtained in 66% of treated cases; the majority of these responses were seen after CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone). The refractory/relapsed disease rate was 54%. Death occurred in 53% of patients, with a median overall survival of 15 months. Sex, CD41 count, viral load, clinical stage, EBV status, primary site of involvement, and use of CHOP failed to show an association with survival. PBL is an aggressive B-cell lymphoma that presents in both oral and extra-oral sites of chronically HIV-infected immunosuppressed young men. Am. J. Hematol. 83:804-809, 2008. V

show abstract

“…Plasmablastic lymphoma with IgH/MYC translocation has also been reported (11). IgH/MYC translocation is detected in 79.1% in AIDS-NHL (2).…”

Section: Clinicopathologic Characteristics Representing Distinct Entimentioning

confidence: 99%

CD20-Negative CD138-Positive Leukemic Large Cell Lymphoma with Plasmablastic Differentiation with an IgH/MYC Translocation in an HIV-Positive Patient

et al. 2009

View full text Add to dashboard Cite

show abstract

Aids-related plasmablastic lymphoma of the oral cavity associated with an IgH/MYC translocation treatment with autologous stem-cell transplantation in a patient with severe haemophilia-A

Cited by 43 publications

References 9 publications

Dominant genetic aberrations and coexistent EBV infection in HIV-related oral plasmablastic lymphomas

Dominant genetic aberrations and coexistent EBV infection in HIV-related oral plasmablastic lymphomas

HIV‐associated plasmablastic lymphoma: Lessons learned from 112 published cases

CD20-Negative CD138-Positive Leukemic Large Cell Lymphoma with Plasmablastic Differentiation with an IgH/MYC Translocation in an HIV-Positive Patient

Contact Info

Product

Resources

About